home / stock / qsam / qsam quote
Last: | $8.30 |
---|---|
Change Percent: | 6.63% |
Open: | $7.75 |
Close: | $8.30 |
High: | $8.3 |
Low: | $7.744 |
Volume: | 133,563 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.3 | $7.75 | $8.3 | $8.3 | $7.744 | 133,563 | 05-02-2024 |
$7.75 | $7.8 | $7.75 | $7.8 | $7.7 | 36,481 | 05-01-2024 |
$7.8 | $7.9 | $7.8 | $7.9 | $7.8 | 5,002 | 04-30-2024 |
$8 | $8 | $8 | $8.4 | $7.85 | 28,384 | 04-29-2024 |
$8 | $8.09 | $8 | $8.39 | $7.9 | 18,914 | 04-26-2024 |
$8.09 | $8.33 | $8.09 | $8.33 | $7.85 | 23,258 | 04-25-2024 |
$8.25 | $8.34 | $8.25 | $8.34 | $8.2 | 13,392 | 04-24-2024 |
$8.14 | $8 | $8.14 | $8.14 | $8 | 2,957 | 04-23-2024 |
$8.14 | $8 | $8.14 | $8.14 | $8 | 3,155 | 04-22-2024 |
$8.05 | $7.8 | $8.05 | $8.05 | $7.75 | 8,300 | 04-19-2024 |
$7.78 | $7.56 | $7.78 | $7.88 | $7.47 | 12,068 | 04-18-2024 |
$7.4 | $7.4 | $7.4 | $7.4 | $7.38 | 3,701 | 04-17-2024 |
$7.4 | $7.4 | $7.4 | $7.4 | $7.29 | 4,116 | 04-16-2024 |
$7.4 | $7.3 | $7.4 | $7.4 | $7.29 | 3,800 | 04-15-2024 |
$7.4 | $7.25 | $7.4 | $7.4 | $7.25 | 10,389 | 04-12-2024 |
$7.25 | $7.25 | $7.25 | $7.25 | $7.15 | 7,198 | 04-11-2024 |
$7.25 | $7.3 | $7.25 | $7.3 | $7.22 | 1,600 | 04-10-2024 |
$7.4 | $7.4 | $7.4 | $7.4 | $7.4 | 200 | 04-09-2024 |
$7.4 | $7.4 | $7.4 | $7.4 | $7.4 | 811 | 04-08-2024 |
$7.45 | $7.38 | $7.45 | $7.45 | $7.25 | 9,675 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc . (OTCQB: QSAM) (“ QSAM ” or the “ Company ”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par...
QSAM Biosciences (OTCQB: QSAM) , a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a definitive agreement and plan of merger pr...